Abstract Number: 0955 • ACR Convergence 2020
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Intravenous immunoglobulin (IVIg) has long been…Abstract Number: 1138 • ACR Convergence 2020
Estimation of Clinically Important Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Measures in Juvenile Myositis
Background/Purpose: Juvenile myositis (JM) causes weakness, rashes, pain, and fatigue, thereby impacting health-related quality of life (HRQoL). Patient-Reported Outcomes Measurement Information System (PROMIS®) measures have…Abstract Number: 0956 • ACR Convergence 2020
An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions
Background/Purpose: Skin lesions in dermatomyositis (DM) patients are common, frequently refractory, and have prognostic significance. Histologically, DM lesions appear similar to cutaneous lupus erythematosus (CLE)…Abstract Number: 1404 • ACR Convergence 2020
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…Abstract Number: 0995 • ACR Convergence 2020
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…Abstract Number: 1555 • ACR Convergence 2020
18F-NaF PET/CT Identifies Active Calcium Uptake in Calcinosis Due to Dermatomyositis and Scleroderma
Background/Purpose: Ectopic soft tissue deposition of hydroxyapatite (calcinosis) is a frequent and morbid complication of dermatomyositis and scleroderma with no known effective pharmacologic treatment. 18F-NaF…Abstract Number: 1058 • ACR Convergence 2020
The Relationship of Different Muscle Enzymes in Adult Myositis Patients
Background/Purpose: Muscle enzymes are a core set measure (CSM) in clinical trials. The 2016 ACR/EULAR myositis response criteria and the IMACS definition of improvement recommend…Abstract Number: 1556 • ACR Convergence 2020
Assessing Calcinosis in Dermatomyositis with Computed Tomography and Calcium Scoring
Background/Purpose: Calcinosis is a condition in which calcium salts are deposited in and around soft tissue and is observed in up to 30% of adult…Abstract Number: 1061 • ACR Convergence 2020
Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers
Background/Purpose: The concept of idiopathic inflammatory myopathy (IIM) flare is widely used, although no consensus definition exists. Studies have demonstrated the feasibility and utility of…Abstract Number: 1639 • ACR Convergence 2020
Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
Background/Purpose: There is significant unmet need for new treatments to achieve disease control in dermatomyositis (DM), because of limited efficacy or toxicity of immunosuppressive agents…Abstract Number: 1062 • ACR Convergence 2020
Dermatomyositis: A Dermatology-Rheumatology Clinic Retrospective Analysis
Background/Purpose: Dermatomyositis (DM) can be categorized into two major subtypes: clinically amyopathic dermatomyositis (CADM) and classic dermatomyositis (CDM). In this study, we aimed to identify characteristics…Abstract Number: 1695 • ACR Convergence 2020
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
Background/Purpose: A subset of juvenile dermatomyositis (JDM), clinically amyopathic dermatomyositis (CADM), is uncommon and mainly described in adults. CADM is classically characterized by skin ulcerations,…Abstract Number: 1063 • ACR Convergence 2020
Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro
Background/Purpose: Spirulina, a popular herbal supplement, stimulates the immune system, as determined by in vitro and in vivo studies. Our recent epidemiologic data suggest that Spirulina…Abstract Number: 1916 • ACR Convergence 2020
KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model
Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are…Abstract Number: 1065 • ACR Convergence 2020
Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis
Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 24
- Next Page »